06:08 , May 20, 2019 |  BioCentury  |  Finance

Boehringer Ingelheim, UCB venture arms seed hearing loss newco Rinri

Seven years after its first foray into hearing loss, Boehringer Ingelheim Venture Fund is investing in U.K. stem cell therapy company Rinri. On May 20, Boehringer's corporate venture fund co-led a £1.4 million ($1.8 million)...
02:27 , May 18, 2018 |  BC Week In Review  |  Financial News

Acousia raises $12M in series B

Hearing loss company Acousia Therapeutics GmbH (Tübingen, Germany) raised €10 million ($12 million) on May 14 in a series B round led by LBBW Venture Capital. Fellow new investors Creathor Ventures and Bregua Corp. and...
12:05 , May 14, 2018 |  BC Extra  |  Financial News

Acousia raises €10M in series B

Hearing loss company Acousia Therapeutics GmbH (Tübingen, Germany) raised €10 million ($12 million) in a series B round led by LBBW Venture Capital. Fellow new investors Creathor Ventures and Bregua Corp. and existing investors Boehringer...
19:41 , Jun 2, 2017 |  BioCentury  |  Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
22:03 , Jan 6, 2017 |  BC Week In Review  |  Company News

Axxam, Acousia deal

Axxam transferred undisclosed assets to Acousia's R&D programs. Acousia is developing small molecules to treat sensorineural hearing loss and to prevent hearing loss in at-risk patients. Last month, Axxam participated in Acousia’s €2.5 million ($2.6...
17:18 , Dec 16, 2016 |  BC Week In Review  |  Financial News

Acousia completes venture financing

Acousia raised €2.5 million ($2.6 million) in a venture round led by Boehringer Ingelheim Venture Fund. KfW and Axxam S.p.A. also participated. Acousia Therapeutics GmbH , Tübingen, Germany ...
08:00 , Jan 4, 2016 |  BioCentury  |  Emerging Company Profile

Regrowing hearing

Acousia Therapeutics GmbH is developing small molecules to treat sensorineural hearing loss that could lead to better speech perception than a clinical-stage gene therapy that also aims to regenerate hair cells. With an investment from...